Cardio Diagnostics Company Insiders
| CDIOW Stock | USD 0.09 0.01 5.80% |
Cardio Diagnostics employs about 7 people. The company is managed by 6 executives with a total tenure of roughly 17 years, averaging almost 2.0 years of service per executive, having 1.17 employees per reported executive. Recap of Cardio Diagnostics' management performance can provide insight into the venture performance.
Cardio |
Cardio Diagnostics Management Team Effectiveness
The company has return on total asset (ROA) of (0.9795) % which means that it has lost $0.9795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.9327) %, meaning that it generated substantial loss on money invested by shareholders. Cardio Diagnostics' management efficiency ratios could be used to measure how well Cardio Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.24 in 2024. Return On Capital Employed is likely to drop to -2.1 in 2024. At this time, Cardio Diagnostics' Non Current Assets Total are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.12 in 2024, whereas Other Current Assets are likely to drop slightly above 974.7 K in 2024.Common Stock Shares Outstanding is likely to drop to about 7.3 M in 2024
Cardio Diagnostics Workforce Comparison
Cardio Diagnostics Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 150. Cardio Diagnostics holds roughly 7.0 in number of employees claiming about 5% of equities under Health Care industry.
Cardio Diagnostics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cardio Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cardio Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cardio Diagnostics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Levy Oded over a month ago Disposition of tradable shares by Levy Oded of Cardio Diagnostics subject to Rule 16b-3 | ||
Philibert Robert over three months ago Acquisition by Philibert Robert of 16000 shares of Cardio Diagnostics at 0.6 subject to Rule 16b-3 | ||
Sim Brandon over three months ago Acquisition by Sim Brandon of tradable shares of Cardio Diagnostics subject to Rule 16b-3 |
Cardio Diagnostics Notable Stakeholders
A Cardio Diagnostics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cardio Diagnostics often face trade-offs trying to please all of them. Cardio Diagnostics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cardio Diagnostics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Meeshanthini Dogan | CEO CoFounder | Profile | |
| Esq JD | Chief Officer | Profile | |
| Timur Dogan | Chief Officer | Profile | |
| Khullani JD | Vice Strategy | Profile | |
| MBA JD | CFO Director | Profile | |
| Khullani Abdullah | VP Strategy | Profile |
About Cardio Diagnostics Management Performance
The success or failure of an entity such as Cardio Diagnostics often depends on how effective the management is. Cardio Diagnostics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cardio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cardio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.13) | (2.24) | |
| Return On Capital Employed | (2.00) | (2.10) | |
| Return On Assets | (1.88) | (1.97) | |
| Return On Equity | (2.83) | (2.97) |
Please note, the imprecision that can be found in Cardio Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cardio Diagnostics Holdings. Check Cardio Diagnostics' Beneish M Score to see the likelihood of Cardio Diagnostics' management manipulating its earnings.
Cardio Diagnostics Workforce Analysis
Traditionally, organizations such as Cardio Diagnostics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cardio Diagnostics within its industry.Cardio Diagnostics Manpower Efficiency
Return on Cardio Diagnostics Manpower
| Revenue Per Employee | 2.4K | |
| Revenue Per Executive | 2.8K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 1.4M | |
| Working Capital Per Employee | 274.9K | |
| Working Capital Per Executive | 320.8K |
Additional Tools for Cardio Stock Analysis
When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.